Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026

Key Takeaway: Enanta Pharmaceuticals is set to present data regarding its Respiratory Syncytial Virus and STAT6 inhibitor programs at the upcoming American Thoracic Society International Conference in 2026. The presentation aims to highlight the company's advancements in these therapeutic areas. Further details on the data to be presented have not been disclosed.